Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients
NCT02432976 on ClinicalTrials.gov · last registry update 2021-03-09
Finished January 2017, after enrolling 64 people. Primary outcome, as filed: Variation of the SF-36 score value at 3-months.
- Status
- COMPLETED
- Phase
- P2/P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Centre Hospitalier Universitaire de Besancon
- Sponsor type
- Other
- Enrollment
- 64
- Started
- 2015-05
- Primary completion
- 2017-01 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Variation of the SF-36 score value at 3-months
Conditions studied
Quality of Life
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.